- Generic Name:
- Drug Type:
- Monoclonal antibody
- How the Drug is Given:
Indications and Usage
is FDA approved for the treatment of:
- Adult patients with non-Hodgkin lymphoma (NHL)
- Relapsed or refractory, low grade or follicular, CD20-positive Bcell NHL as a single agent.
- Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to RITUXAN in combination with chemotherapy, as single-agent maintenance therapy.
- Non-progressing (including stable disease), low-grade, CD20- positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy.
- Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens.
- Pediatric patients aged 6 months and older with mature B-cell NHL and mature B-cell acute leukemia (B-AL)
- Previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy.
- Adult patients with chronic lymphocytic leukemia (CLL)
- Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC).
Side effects needing medical attention
Fever; chills; difficulty breathing or shortness of breath; sensation of tongue or throat swelling; hives; itching; weakness; headache; nausea; vomiting; flushing; palpitations; chest pain; rash; dizziness; coughing; unusual tiredness or fatigue; unusual bruising or bleeding; muscle or joint pain; abdominal pain; diarrhea.
In patients with prior hepatitis B (HBV) infection, HBV reactivation may occur when the body's immune system is impaired.